CERS

Stats

Summary

cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.

Market Cap: 438 Million

Primary Exchange: NASDAQ

Website: http://www.cerus.com/

Shares Outstanding: 181 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 2.591239138086858

Sector: Manufacturing

Industry: Surgical and Medical Instrument Manufacturing

Ethical Flags

Longest drawdown: 2307 trading days

From: 2014-02-25 To: 2020-12-21

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor